A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs Poly ICLC (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 05 Nov 2024 New trial record